Revenue declined 0.9% year-over-year to SEK 405.1 million, with adjusted EBITDA at 5.7% due to SEK 8 million in restructuring costs, mainly in Finland. Defense and life science segments showed growth, and a strong order backlog positions the company for improved profitability in H2 2026.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.